Globally the potential link between systemic inflammation and tumour angiogenesis and thus the hypothetical predictive role of inflammatory markers during antiangiogenetic therapies has been evaluated in CRC patients treated with bevacizumab with interesting insights into the biological mechanisms underlying the interaction between inflammation, angiogenesis and anti-VEGF therapy [31]. The gene discussed is VEGFA; the disease is neoplasm.